Targeting cytoplasmic Tau aggregates by active and passive immunotherapy has shown promise in rodent models of Alzheimer's disease (AD), and effects on both intracellular and (unconventionally secreted) extracellular Tau have been discussed (Congdon & Sigurdsson, 2018). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.